Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...

Prior to his time at Intercept, Mr. Durso spent over two decades at Sanofi, where he held multiple senior leadership positions, including Chief Commercial Officer of the Company’s Global Diabetes ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Whitten confirmed his new role in a message to GeekWire. Whitten was previously CEO of Cruise, the GM-backed self-driving company that recently halted its robotaxi program. Whitten was also CTO at ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults and pediatric patients with diabetes mellitus. The regulatory ...

President Donald Trump met Friday afternoon with Nvidia Corp. Chief Executive Jensen Huang at the White House, with their get-together coming as the chip giant has faced questions due to the big ...

Self-driving cars have a long way to go before they become common on Uber, the ride-hailing service's CEO said Wednesday. Developers of self-driving cars, such as Tesla and Waymo, are making the ...